Genetic changes are a significant cause of infertility, impacting over 15% of the global population. TLE6, a major protein ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

In gene and cell therapy, RNP-mediated CRISPR gene editing is quickly emerging as the new norm. For many gene editing firms, GenScript has created hundreds of Cas9, Cas12a, Cas13a, MAD7 ...

Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...

Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio ...

Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...

In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR ...

CRISPR gene-editing technology presents a possible solution for feeding a growing population, but incorporating CRISPR into ...

Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Editas Medicine (EDIT – Research Report) yesterday and set a ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...

Infertility is a major global challenge associated with physiological and psychological impact. Genetic mutations that affect early embryonic ...